AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Significant Growth in Short Interest

AquaBounty Technologies, Inc. (NASDAQ:AQB) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 423,300 shares, an increase of 452.6% from the December 15th total of 76,600 shares. Approximately 11.7% of the shares of the stock are sold short. Based on an average daily volume of 425,500 shares, the short-interest ratio is presently 1.0 days.

AquaBounty Technologies Price Performance

Shares of AQB traded up $0.03 during mid-day trading on Wednesday, reaching $0.80. The company had a trading volume of 551,424 shares, compared to its average volume of 402,889. The company has a market capitalization of $3.10 million, a price-to-earnings ratio of -0.04 and a beta of 1.17. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.98 and a current ratio of 3.02. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $1.13. AquaBounty Technologies has a 1-year low of $0.47 and a 1-year high of $2.79.

AquaBounty Technologies (NASDAQ:AQB) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.88) earnings per share for the quarter, meeting the consensus estimate of ($0.88). AquaBounty Technologies had a negative return on equity of 18.20% and a negative net margin of 5,842.69%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. During the same quarter last year, the business posted ($1.60) EPS. Analysts expect that AquaBounty Technologies will post -4.86 EPS for the current year.

About AquaBounty Technologies

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.